TRIAGING OF PATIENTS HAVING ASYMPTOMATIC HEMATURIA USING GENOTYPIC AND PHENOTYPIC BIOMARKERS
New methods for treating patents for urothelial cancer (UC) include combining selected phenotypic variables with levels of genotypic expression into a metric, the "G+P INDEX." The G+P INDEX combines age, sex, smoking history, presence of hematuria, and frequency of hematuria with genotypic...
Gespeichert in:
| Hauptverfasser: | , , , , , |
|---|---|
| Format: | Patent |
| Sprache: | eng ; fre ; ger |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | KUMAR, Satish KAVALIERIS, Laimonis DARLING, David SUTTIE, James, Miller O'SULLIVAN, Paul DALPHIN, Mark |
| description | New methods for treating patents for urothelial cancer (UC) include combining selected phenotypic variables with levels of genotypic expression into a metric, the "G+P INDEX." The G+P INDEX combines age, sex, smoking history, presence of hematuria, and frequency of hematuria with genotypic expression of the genetic markers, MDK, CDC2, HOXA13, IGFBP5, and optionally IL8Rb, then determining of the G+P INDEX value obtained for a patient is within one of three groups, either: (1) at High Risk of UC, (2) at Risk of UC, or (3) at Low Risk of UC. For groups 1 and 2, further clinical and laboratory work up or treatment is indicated, and patients in group 3 are monitored periodically to determine the need for further clinical workup. Using the G+P INDEX can save substantial time, effort, and funds by avoiding unnecessary medical diagnostic procedures for patients having or are at risk for developing UC. |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_EP3071973B1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>EP3071973B1</sourcerecordid><originalsourceid>FETCH-epo_espacenet_EP3071973B13</originalsourceid><addsrcrecordid>eNrjZIgJCfJ0dPf0c1fwd1MIcAzxdPULCVbwcAwDCTkGR_oGhPj7AoWdFTxcgXQoULVCaDBI0t3Vzz8kMgAo4-jnohDgAec6eQJ1BHm7BgXzMLCmJeYUp_JCaW4GBTfXEGcP3dSC_PjU4oLE5NS81JJ41wBjA3NDS3NjJ0NjIpQAAI9zMnA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>TRIAGING OF PATIENTS HAVING ASYMPTOMATIC HEMATURIA USING GENOTYPIC AND PHENOTYPIC BIOMARKERS</title><source>esp@cenet</source><creator>KUMAR, Satish ; KAVALIERIS, Laimonis ; DARLING, David ; SUTTIE, James, Miller ; O'SULLIVAN, Paul ; DALPHIN, Mark</creator><creatorcontrib>KUMAR, Satish ; KAVALIERIS, Laimonis ; DARLING, David ; SUTTIE, James, Miller ; O'SULLIVAN, Paul ; DALPHIN, Mark</creatorcontrib><description>New methods for treating patents for urothelial cancer (UC) include combining selected phenotypic variables with levels of genotypic expression into a metric, the "G+P INDEX." The G+P INDEX combines age, sex, smoking history, presence of hematuria, and frequency of hematuria with genotypic expression of the genetic markers, MDK, CDC2, HOXA13, IGFBP5, and optionally IL8Rb, then determining of the G+P INDEX value obtained for a patient is within one of three groups, either: (1) at High Risk of UC, (2) at Risk of UC, or (3) at Low Risk of UC. For groups 1 and 2, further clinical and laboratory work up or treatment is indicated, and patients in group 3 are monitored periodically to determine the need for further clinical workup. Using the G+P INDEX can save substantial time, effort, and funds by avoiding unnecessary medical diagnostic procedures for patients having or are at risk for developing UC.</description><language>eng ; fre ; ger</language><subject>BEER ; BIOCHEMISTRY ; CHEMISTRY ; COMPOSITIONS OR TEST PAPERS THEREFOR ; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES ; ENZYMOLOGY ; MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS ; METALLURGY ; MICROBIOLOGY ; MUTATION OR GENETIC ENGINEERING ; PROCESSES OF PREPARING SUCH COMPOSITIONS ; SPIRITS ; VINEGAR ; WINE</subject><creationdate>2020</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20201104&DB=EPODOC&CC=EP&NR=3071973B1$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,776,881,25542,76290</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20201104&DB=EPODOC&CC=EP&NR=3071973B1$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>KUMAR, Satish</creatorcontrib><creatorcontrib>KAVALIERIS, Laimonis</creatorcontrib><creatorcontrib>DARLING, David</creatorcontrib><creatorcontrib>SUTTIE, James, Miller</creatorcontrib><creatorcontrib>O'SULLIVAN, Paul</creatorcontrib><creatorcontrib>DALPHIN, Mark</creatorcontrib><title>TRIAGING OF PATIENTS HAVING ASYMPTOMATIC HEMATURIA USING GENOTYPIC AND PHENOTYPIC BIOMARKERS</title><description>New methods for treating patents for urothelial cancer (UC) include combining selected phenotypic variables with levels of genotypic expression into a metric, the "G+P INDEX." The G+P INDEX combines age, sex, smoking history, presence of hematuria, and frequency of hematuria with genotypic expression of the genetic markers, MDK, CDC2, HOXA13, IGFBP5, and optionally IL8Rb, then determining of the G+P INDEX value obtained for a patient is within one of three groups, either: (1) at High Risk of UC, (2) at Risk of UC, or (3) at Low Risk of UC. For groups 1 and 2, further clinical and laboratory work up or treatment is indicated, and patients in group 3 are monitored periodically to determine the need for further clinical workup. Using the G+P INDEX can save substantial time, effort, and funds by avoiding unnecessary medical diagnostic procedures for patients having or are at risk for developing UC.</description><subject>BEER</subject><subject>BIOCHEMISTRY</subject><subject>CHEMISTRY</subject><subject>COMPOSITIONS OR TEST PAPERS THEREFOR</subject><subject>CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES</subject><subject>ENZYMOLOGY</subject><subject>MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS</subject><subject>METALLURGY</subject><subject>MICROBIOLOGY</subject><subject>MUTATION OR GENETIC ENGINEERING</subject><subject>PROCESSES OF PREPARING SUCH COMPOSITIONS</subject><subject>SPIRITS</subject><subject>VINEGAR</subject><subject>WINE</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2020</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZIgJCfJ0dPf0c1fwd1MIcAzxdPULCVbwcAwDCTkGR_oGhPj7AoWdFTxcgXQoULVCaDBI0t3Vzz8kMgAo4-jnohDgAec6eQJ1BHm7BgXzMLCmJeYUp_JCaW4GBTfXEGcP3dSC_PjU4oLE5NS81JJ41wBjA3NDS3NjJ0NjIpQAAI9zMnA</recordid><startdate>20201104</startdate><enddate>20201104</enddate><creator>KUMAR, Satish</creator><creator>KAVALIERIS, Laimonis</creator><creator>DARLING, David</creator><creator>SUTTIE, James, Miller</creator><creator>O'SULLIVAN, Paul</creator><creator>DALPHIN, Mark</creator><scope>EVB</scope></search><sort><creationdate>20201104</creationdate><title>TRIAGING OF PATIENTS HAVING ASYMPTOMATIC HEMATURIA USING GENOTYPIC AND PHENOTYPIC BIOMARKERS</title><author>KUMAR, Satish ; KAVALIERIS, Laimonis ; DARLING, David ; SUTTIE, James, Miller ; O'SULLIVAN, Paul ; DALPHIN, Mark</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_EP3071973B13</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng ; fre ; ger</language><creationdate>2020</creationdate><topic>BEER</topic><topic>BIOCHEMISTRY</topic><topic>CHEMISTRY</topic><topic>COMPOSITIONS OR TEST PAPERS THEREFOR</topic><topic>CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES</topic><topic>ENZYMOLOGY</topic><topic>MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS</topic><topic>METALLURGY</topic><topic>MICROBIOLOGY</topic><topic>MUTATION OR GENETIC ENGINEERING</topic><topic>PROCESSES OF PREPARING SUCH COMPOSITIONS</topic><topic>SPIRITS</topic><topic>VINEGAR</topic><topic>WINE</topic><toplevel>online_resources</toplevel><creatorcontrib>KUMAR, Satish</creatorcontrib><creatorcontrib>KAVALIERIS, Laimonis</creatorcontrib><creatorcontrib>DARLING, David</creatorcontrib><creatorcontrib>SUTTIE, James, Miller</creatorcontrib><creatorcontrib>O'SULLIVAN, Paul</creatorcontrib><creatorcontrib>DALPHIN, Mark</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>KUMAR, Satish</au><au>KAVALIERIS, Laimonis</au><au>DARLING, David</au><au>SUTTIE, James, Miller</au><au>O'SULLIVAN, Paul</au><au>DALPHIN, Mark</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>TRIAGING OF PATIENTS HAVING ASYMPTOMATIC HEMATURIA USING GENOTYPIC AND PHENOTYPIC BIOMARKERS</title><date>2020-11-04</date><risdate>2020</risdate><abstract>New methods for treating patents for urothelial cancer (UC) include combining selected phenotypic variables with levels of genotypic expression into a metric, the "G+P INDEX." The G+P INDEX combines age, sex, smoking history, presence of hematuria, and frequency of hematuria with genotypic expression of the genetic markers, MDK, CDC2, HOXA13, IGFBP5, and optionally IL8Rb, then determining of the G+P INDEX value obtained for a patient is within one of three groups, either: (1) at High Risk of UC, (2) at Risk of UC, or (3) at Low Risk of UC. For groups 1 and 2, further clinical and laboratory work up or treatment is indicated, and patients in group 3 are monitored periodically to determine the need for further clinical workup. Using the G+P INDEX can save substantial time, effort, and funds by avoiding unnecessary medical diagnostic procedures for patients having or are at risk for developing UC.</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | eng ; fre ; ger |
| recordid | cdi_epo_espacenet_EP3071973B1 |
| source | esp@cenet |
| subjects | BEER BIOCHEMISTRY CHEMISTRY COMPOSITIONS OR TEST PAPERS THEREFOR CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES ENZYMOLOGY MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS METALLURGY MICROBIOLOGY MUTATION OR GENETIC ENGINEERING PROCESSES OF PREPARING SUCH COMPOSITIONS SPIRITS VINEGAR WINE |
| title | TRIAGING OF PATIENTS HAVING ASYMPTOMATIC HEMATURIA USING GENOTYPIC AND PHENOTYPIC BIOMARKERS |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-29T01%3A08%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=KUMAR,%20Satish&rft.date=2020-11-04&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EEP3071973B1%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |